TPST - Tempest to Participate in Upcoming Investor Conferences
BRISBANE, Calif., May 21, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class i targeted and immune-mediated therapeutics to fight cancer, today announced that management will participate in the following upcoming investor conferences:
- TD Cowen's 5th Annual Oncology Innovation Summit – Fireside chat on Wednesday, May 29, 2024 at 2:00 p.m. ET
- Jefferies Global Healthcare Conference – Presentation on Wednesday, June 5, 2024 at 4:00 p.m. ET
To access the live or archived recording of the discussions, please visit the investor section of the Tempest website at https://ir.tempesttx.com .
About Tempest Therapeutics
Tempest Therapeutics is a clinical-stage biotechnology company advancing a diverse portfolio of small molecule product candidates containing tumor-targeted and/or immune-mediated mechanisms with the potential to treat a wide range of tumors. The company’s novel programs range from early research to later-stage investigation in a randomized global study in first-line cancer patients. Tempest is headquartered in Brisbane, California. More information about Tempest can be found on the company’s website at www.tempesttx.com .
Investor & Media Contacts
Sylvia Wheeler
Wheelhouse Life Science Advisors
swheeler@wheelhouselsa.com
Aljanae Reynolds
Wheelhouse Life Science Advisors
areynolds@wheelhouselsa.com
| i If approved by the FDA |